Painful Diabetic Peripheral Neuropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Painful Diabetic Peripheral Neuropathy Market Outlook

Thelansis’s “Painful Diabetic Peripheral Neuropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Painful Diabetic Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Painful Diabetic Peripheral Neuropathy Overview

Painful Diabetic Peripheral Neuropathy characteristically presents with a tingling sensation, numbness, burning, excruciating stabbing type of pain, sometimes intractable. It may be associated with paraesthesia and hyperesthesia coupled with deep aching in the feet or hands. Poor glycaemic control is a major risk factor for the development of diabetic neuropathy. It has been observed that an estimated 50% of patients develop Painful Diabetic Peripheral Neuropathy 25 years after the initial diagnosis of diabetes mellitus. The prevalence of PDN ranges from 10% to 20% of patients with diabetes, and in those with diabetic neuropathy, it ranges from 40% to 50%. The underlying mechanism for the generation of pain is hyperexcitability in primary afferent nociceptors, which occurs due to damage to peripheral nerves. This in turn, leads to hyperexcitability in central neurons and the generation of spontaneous impulses within the axon and the dorsal root ganglion of these peripheral nerves.

• The ~26% to 52% of diabetic patients develop Painful Diabetic Peripheral Neuropathy. Prevalence results included both painful and nonpainful diabetic peripheral neuropathy.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: